Blurbs

J.P. Morgan Remains a Buy on IDEAYA Biosciences (IDYA)

In a report released on August 23, Anupam Rama from J.P. Morgan maintained a Buy rating on IDEAYA Biosciences (IDYAResearch Report), with a price target of $18.00. The company’s shares closed yesterday at $10.38.

Rama covers the Healthcare sector, focusing on stocks such as Apellis Pharmaceuticals, Springworks Therapeutics, and Elevation Oncology. According to TipRanks, Rama has an average return of 3.1% and a 46.49% success rate on recommended stocks.

In addition to J.P. Morgan, IDEAYA Biosciences also received a Buy from Oppenheimer’s Matthew Biegler in a report issued on August 16. However, on August 15, Stifel Nicolaus downgraded IDEAYA Biosciences (NASDAQ: IDYA) to a Hold.

See the top stocks recommended by analysts >>

Based on IDEAYA Biosciences’ latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $5.85 million and a GAAP net loss of $22.06 million. In comparison, last year the company earned a revenue of $8.76 million and had a GAAP net loss of $10.95 million

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

IDEAYA Biosciences, Inc. develops cancer therapeutics. It is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company operates and manages its business as one operating and reportable segment, which is the business of research and development for oncology-focused precision medicine. The company was founded by Yujiro S. Hata and Jeffrey Hager in June 2015 and is headquartered in South San Francisco, CA.

Read More on IDYA:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More